FOXP3 in sequential biopsies of progressive mycosis fungoides

American Journal of Dermatopathology

Volumn 34, Issue 3, 2012, Pages 263-265

  Fried, Isabella ^a   Cerroni, Lorenzo ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

FOXP3; Mycosis fungoides; regulatory T cells

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER STAGING; CELL INFILTRATION; CELL POPULATION; CELL SIZE; CELL STRUCTURE; CLINICAL ARTICLE; DISEASE COURSE; EPIDERMIS; HUMAN; HUMAN TISSUE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR BIOPSY;

CELL COUNT; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860372882     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31823062db     Document Type: Article

References (24)

1. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;18:3668-3676. (Pubitemid 41095205)
2. Cook MG, Spatz A, Brocker EB, et al. Identification of histological features associated with metastatic potential in thin (,1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol. 2002;2:188-193. (Pubitemid 34567606)
3. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (, or =1.5 mm): identification of risk factors indicative of progression. Cancer. 1999;5:1067-1076. (Pubitemid 29115585)
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;36:6199-6206.
5. Santillan AA, Messina JL, Marzban SS, et al. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol. 2010;3:481-486.
6. Shibata K, Ajiro K. Cell cycle-dependent suppressive effect of histone H1 on mitosis-specific H3 phosphorylation. J Biol Chem. 1993;25:18431-18434. (Pubitemid 23273768)
7. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;6:348-360. (Pubitemid 27510848)
8. Gurley LR, D'Anna JA, Barham SS, et al. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem. 1978;1:1-15. (Pubitemid 8286682)
9. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;11:1532-1536. (Pubitemid 39425522)
10. Kim YJ, Ketter R, Steudel WI, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;1:118-125. (Pubitemid 47121724)
11. Fukushima S, Terasaki M, Sakata K, et al. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol. 2009;2:51-57.
12. Casper DJ, Ross KI, Messina JL, et al. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol. 2010;7:650-654.
13. Angi M, Damato B, Kalirai H, et al. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol. 2009;89:e155-e160.
14. Bland JM, Altman DG. A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med. 1990;5:337-340. (Pubitemid 20350333)
15. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-2205.
16. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;6:1488-1498. (Pubitemid 36297779)
17. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;2:117-122. (Pubitemid 351441982)
18. Rudolph P, Peters J, Lorenz D, et al. Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. Hum Pathol. 1998;11:1216-1222. (Pubitemid 28525520)
19. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;12:1571-1576. (Pubitemid 37486620)
20. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;5:657-664. (Pubitemid 44265019)
21. Glatz K, Hartmann C, Antic M, et al. Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis. Am J Dermatopathol. 2010;7:643-649.
22. Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.
23. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;1:83-89. (Pubitemid 43740213)
24. Zhang X, Li X, Marshall JB, et al. Phosphoserines on maize centromeric histone H3 and histone H3 demarcate the centromere and pericentromere during chromosome segregation. Plant Cell. 2005;2:572-583. (Pubitemid 41672976)